Novo Nordisk A/S Class Action Lawsuit Investigation

Berger Montague is investigating claims against Novo Nordisk A/S (NYSE: NVO) after a class action lawsuit was filed. The lawsuit alleges that the company misled investors by lowering its sales and profit guidance for the second half of fiscal 2025. Novo's stock price plummeted from $69.00 to $53.94 per share, a one-day decline of more than 21%. Investors who purchased or acquired Novo securities between May 7, 2025, and July 28, 2025, may seek to be appointed as lead plaintiff representative by September 30, 2025.

Novo Nordisk A/S (NYSE: NVO), a global pharmaceutical company, is facing a class action lawsuit following the filing of a claim against the company. The lawsuit alleges that Novo misled investors by lowering its sales and profit guidance for the second half of fiscal 2025.

The complaint, filed by Berger Montague PC, states that Novo's representations regarding its growth potential were overstated and failed to account for the impact of the personalization exception to the compounded GLP-1 exclusion. Additionally, the complaint alleges that Novo misrepresented the likelihood that patients using compounded GLP-1s would transition to Novo's branded alternatives and overstated the size of the GLP-1 market and its ability to penetrate that market to sustain growth.

On July 29, 2025, Novo announced it was lowering its sales and profit outlook ahead of reporting its results for the second quarter of fiscal year 2025. The Company attributed the guide down to "lowered growth expectations for the second half of 2025" for both Wegovy and Ozempic due to "the persistent use of compounded GLP-1s, slower-than-expected market expansion and competition." Following this news, the price of Novo's common stock declined dramatically. From a closing market price of $69.00 per share on July 28, 2025, Novo's stock price fell to $53.94 per share on July 29, 2025, a decline of about 21.83% in the span of just a single day.

Investors who purchased or acquired Novo securities between May 7, 2025, and July 28, 2025, may seek to be appointed as lead plaintiff representative by September 30, 2025. To learn more about this action, investors are encouraged to contact Berger Montague PC.

Berger Montague PC, a pioneer in securities class action litigation since its founding in 1970, has represented individual and institutional investors for over five decades and serves as lead counsel in courts throughout the United States.

For more information or to discuss your rights, please contact:
- Andrew Abramowitz, Senior Counsel, Berger Montague, (215) 875-3015, aabramowitz@bergermontague.com
- Caitlin Adorni, Berger Montague, (267) 764-4865, cadorni@bergermontague.com

References:
- [1] https://www.prnewswire.com/news-releases/attention-nyse-nvo-investors-contact-berger-montague-about-a-novo-nordisk-as-class-action-lawsuit-302528288.html
- [2] https://www.globenewswire.com/news-release/2025/08/11/3131204/9788/en/NVO-INVESTOR-ALERT-Bronstein-Gewirtz-Grossman-LLC-Announces-that-Novo-Nordisk-A-S-Investors-with-Substantial-Losses-Have-Opportunity-to-Lead-Class-Action-Lawsuit.html
- [3] https://www.morningstar.com/news/pr-newswire/20250812dc50163/attention-nyse-nvo-investors-contact-berger-montague-about-a-novo-nordisk-as-class-action-lawsuit
- [4] https://www.marketscreener.com/news/levi-korsinsky-reminds-shareholders-of-a-lead-plaintiff-deadline-of-september-30-2025-in-novo-nor-ce7c51dad88eff26